My main research area is prostate cancer genetics focusing on identifying new markers both for the risk of getting prostate cancer and for the prognosis of prostate cancer once diagnosed. I have identified several prostate cancer susceptibility loci and was part of the team that identified the first susceptibility loci more than 20 years ago.
I developed STHLM3 - a blood test that combines protein markers, genetic markers and clinical data with an advanced algorithm in order to detect aggressive prostate cancer at an early stage and am PI for the ProBio trial aiming to identify biomarkers predicting treatment response among men with metastatic prostate cancer.